InsidersTradesSigma
Intuitive Surgical INC Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Intuitive Surgical INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Intuitive Surgical INC has recorded 336 reports. Market capitalisation: €150.9bn. The latest transaction was filed on 12 June 2026 (Cession). Among the most active insiders: Brosius Mark. Every trade is openly available.
336
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€8m
41 ops.
Sell Volume
26Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 8,388 of 25,535 companies
60.3
score / 100
Value32
Quality88
FCF yld1.7%
Earn yld1.9%
EV/EBITDA41.7x
ROE17%
Gross mgn66%
Net mgn28%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 June 2026
Declarations336 total
23 sharesCommon StockSEC:0002010300-26-000021:0
25 sharesCommon StockSEC:0002010300-26-000021:1
23 sharesCommon StockSEC:0002010300-26-000019:0
23 sharesCommon StockSEC:0002010300-26-000019:1
23 sharesCommon StockSEC:0002010300-26-000019:2
18 shares@ US$446.040.0000% mcap0.5% of flowCommon StockSEC:0002010300-26-000017:0
18 shares@ US$439.800.0000% mcap0.5% of flowCommon StockSEC:0002010300-26-000017:1
312 shares@ US$547.3650.0% of flowCommon StockSEC:0001610717-25-000418
312 shares@ US$547.360.0001% mcap50.0% of flowCommon StockSEC:0001610717-25-000418:0
22 shares@ US$560.000.8% of flowCommon StockSEC:0001035267-25-000163:0
22 shares@ US$551.970.8% of flowCommon StockSEC:0001035267-25-000158:0
188 shares@ US$208.903.1% of flowCommon StockSEC:0001610717-25-000112:0
1,448 shares@ US$243.2628.6% of flowCommon StockSEC:0001035267-25-000137:0
2,400 shares@ US$90.4944100.0% of flowCommon StockSEC:0001035267-25-000151:0
188 shares@ US$290.331.1% of flowCommon StockSEC:0001035267-25-000135:0
4,000 shares@ US$242.33678.0% of flowCommon StockSEC:0001035267-25-000133:0
739 shares0Common StockSEC:0001035267-25-000129:0
739 shares0Common StockSEC:0001035267-25-000119:0
739 shares0Common StockSEC:0001035267-25-000111:0
739 shares0Common StockSEC:0001035267-25-000115:0
739 shares0Common StockSEC:0001035267-25-000113:0
739 shares0Common StockSEC:0001035267-25-000123:0
1,043 shares0Common StockSEC:0001035267-25-000121:0
739 shares0Common StockSEC:0001035267-25-000117:0
739 shares0Common StockSEC:0001035267-25-000125:0
25 of 336 declarations
About Intuitive Surgical INC
Intuitive Surgical Inc. is a flagship U.S. medtech company listed on the NASDAQ in the United States. Founded in 1995 and headquartered in Sunnyvale, California, the company is widely recognized as the pioneer of robotic-assisted minimally invasive surgery. From an investor’s perspective, ISRG is best understood as a platform business: it sells robotic systems, instruments and accessories, and services, creating a meaningful recurring-revenue profile and a sticky installed base in hospitals and ambulatory settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1035267/000103526725000099/a2024_intuitiveannualrepor.pdf?utm_source=openai)) The company’s core franchise is the da Vinci family of surgical robotic systems, complemented by the Ion endoluminal system for lung biopsy and other endoluminal applications. Intuitive serves a broad range of procedures, including urology, gynecology, general surgery, thoracic surgery, colorectal surgery, and selected ENT applications, depending on regulatory approvals in each market. A major strategic step has been the rollout of da Vinci 5, the company’s newest platform generation, which adds software capabilities and real-time surgical insights aimed at improving workflow efficiency and system performance. ([intuitive.com](https://www.intuitive.com/en-us?utm_source=openai)) Competitive positioning remains one of Intuitive’s key strengths. The company is the global leader in surgical robotics, supported by strong brand equity, a large installed base, broad surgeon familiarity, and an ecosystem of training, clinical support, and service that is difficult for competitors to replicate quickly. That leadership has continued to translate into healthy procedure growth in 2025, with management updates highlighting rising worldwide usage across da Vinci and Ion, as well as increasing adoption of da Vinci 5. ([isrg.intuitive.com](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-preliminary-fourth-quarter-and-full-year-5?utm_source=openai)) Geographically, Intuitive is a U.S.-based company with a global commercial footprint across North America, Europe, and other developed international markets. Recent milestones have reinforced its innovation pipeline: the FDA expanded da Vinci SP indications in 2025, Intuitive introduced new real-time software features for da Vinci 5, enhanced AI and imaging integration in Ion, and received CE Mark approval for da Vinci 5 in Europe. For equity investors, the combination of technology leadership, recurring revenue, and secular adoption of minimally invasive surgery underpins the long-term thesis. ([isrg.intuitive.com](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-fda-clearance-da-vinci-single-port-transanal?utm_source=openai))
